Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Genomic instability in mouse Burkitt lymphoma is dominated by illegitimate genetic recombinations, not point mutations

Abstract

λ-MYC-induced mouse Burkitt lymphoma (BL) harboring the shuttle vector pUR288, which includes a lacZ reporter gene to study mutagenesis, was employed to assess genomic instability associated with MYC deregulation. The frequency of lacZ mutations in lymphomas was elevated only 1.75-fold above that in normal tissue, indicating that mouse BL does not exhibit a phenotype of hypermutability. However, the nature of lacZ mutations was strikingly different in normal tissues and lymphomas. While point mutations comprised approximately 75% of the mutations found in normal tissues, apparent translocations, deletions and inversions constituted the majority of mutations (65%) in lymphomas. Genomic instability in mouse BL thus seems characterized by a preponderance of illegitimate genetic rearrangements in the context of near-background mutant frequencies. SKY analyses of cell lines from primary BL tumors revealed substantial changes in chromosomal structure, confirming the lacZ studies. Bi-allelic deletions of the tumor suppressor p16Ink4a were detected in six out of 16 cell lines, illustrating cellular selection of advantageous mutations. Together, these approaches indicate that MYC may contribute to lymphomagenesis through the dominant mutator effect of inducing chromosomal instability. The results further suggest that a phenotype of hypermutability (elevated mutant frequency) may not always be required for oncogenesis to occur.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Baross-Francis A, Andrew SE, Penney JE, Jirik FR . 1998 Proc. Natl. Acad. Sci. USA 95: 8739–8743

  • Boerrigter ME, Dolle ME, Martus HJ, Gossen JA, Vijg J . 1995 Nature 377: 657–659

  • Buettner VL, Hill KA, Nishino H, Schaid DJ, Frisk CS, Sommer SS . 1996 Oncogene 13: 2407–2413

  • Cole MD, McMahon SB . 1999 Oncogene 18: 2916–2924

  • Coleman AE, Ried T, Janz S . 2000 Genes Chromosomes Cancer 29: 70–74

  • Davis CD, Dacquel EJ, Schut HA, Thorgeirsson SS, Snyderwine EG . 1996 Mutat. Res. 356: 287–296

  • Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL . 1999 Genes Dev. 13: 2658–2669

  • Eischen CM, Woo D, Roussel MF, Cleveland JL . 2001 Mol. Cell. Biol. 21: 5063–5070

  • Felsher DW, Zetterberg A, Zhu J, Tlsty T, Bishop JM . 2000 Proc. Natl. Acad. Sci. USA 97: 10544–10548

  • Gossen JA, de Leeuw WJ, Tan CH, Zwarthoff EC, Berends F, Lohman PH, Knook DL, Vijg J . 1989 Proc. Natl. Acad. Sci. USA 86: 7971–7975

  • Jakubczak JL, Merlino G, French JE, Muller WJ, Paul B, Adhya S, Garges S . 1996 Proc. Natl. Acad. Sci. USA 93: 9073–9078

  • Kohler SW, Provost GS, Fieck A, Kretz PL, Bullock WO, Putman DL, Sorge JA, Short JM . 1991 Environ. Mol. Mutagen. 18: 316–321

  • Kovalchuk AL, Qi CF, Torrey TA, Taddesse-Heath L, Feigenbaum L, Park SS, Gerbitz A, Klobeck G, Hoertnagel K, Polack A, Bornkamm GW, Janz S, Morse HC . 2000 J. Exp. Med. 192: 1183–1190

  • Liyanage M, Coleman A, du Manoir S, Veldman T, McCormack S, Dickson RB, Barlow C, Wynshaw-Boris A, Janz S, Wienberg J, Ferguson-Smith MA, Schröck E, Ried T . 1996 Nat. Genet. 14: 312–315

  • Loeb LA . 1991 Cancer Res. 51: 3075–3079

  • Moore JK, Haber JE . 1996 Nature 383: 644–646

  • Mushinski JF, Mai S . 2002 Crit. Rev. Oncog. In press

  • Roth DB, Wilson JH . 1988 Genetic recombination Kucherlapati R and Smith GR (eds) Washington, DC: American Society for Microbiology pp. 621–654

    Google Scholar 

  • Tomlinson I, Bodmer W . 1999 Nat. Med. 5: 11–12

Download references

Acknowledgements

We wish to thank Dr Jan Vijg, UT at San Antonio, for providing pUR288 mice, Drs Michael Boerrigter, Leven, Inc., Martijn Dollé, UT at San Antonio, and Klaus Felix, NCI, for advice on the pUR288 mutagenesis assay, Danny Wangsa and Viktor Janz, Department of Genetics, NCI, for help with the SKY analysis, Dr Lionel Feigenbaum, SAIC, for generating E-MYC mice, and Wendy DuBois and Taryn Stelter for animal husbandry. These studies were supported in part by a NCI Intramural Research Award to S Janz.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Siegfried Janz.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rockwood, L., Torrey, T., Kim, J. et al. Genomic instability in mouse Burkitt lymphoma is dominated by illegitimate genetic recombinations, not point mutations. Oncogene 21, 7235–7240 (2002). https://doi.org/10.1038/sj.onc.1205697

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205697

Keywords

This article is cited by

Search

Quick links